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Translationally controlled tumor protein (TCTP) is a highly conserved and ubiquitously expressed protein in all eukaryotes—
highlighting its important functions in the cell. Previous studies revealed that TCTP is implicated in many biological processes,
including cell growth, tumor reversion, and induction of pluripotent stem cell. A recent study on the solution structure from
ﬁssion yeast orthologue classiﬁes TCTP under a family of small chaperone proteins. There is growing evidence in the literature
that TCTP is a multifunctional protein and exerts its biological activity at the extracellular and intracellular levels. Although TCTP
is not a tumor-speciﬁc protein, our research group, among several others, focused on the role(s) of TCTP in cancer progression. In
thispaper,wewillsummarizethecurrentscientiﬁcknowledgeofTCTPindiﬀerentaspects,andthepreciseoncogenicmechanisms
of TCTP will be discussed in detail.
1.Introduction
Translationally controlled tumor protein (TCTP) is a highly
conserved multifunctional protein. Since the discovery of
TCTP over two decades ago, the expression level of TCTP
has been investigated in more than 500 tissues and cell types.
Expression levels have been found to vary by nearly two
orders of magnitude between diﬀerent types of tissues [1]
with preferential expression in mitotically active tissues [2].
Two mRNA transcripts have been reported to carry the same
5 UTRbutdiﬀerent3 UTRusingalternativepolyadenylation
signals. The solution structure of TCTP from ﬁssion yeast
alsorevealedstructuralsimilaritywiththeMss4/Dss4protein
family. The expression of TCTP is highly regulated both
at transcriptional and translational levels in addition to a
wide range of extracellular signals. It has been implicated
in many cellular processes, such as cell growth, cell cycle
progression, apoptosis, malignant transformation, and the
regulation of pluripotency. Although TCTP is not a tumor-
speciﬁc protein, the downregulation of TCTP was found
in tumor reversion [3]. Our research group and others
also substantiated the link between TCTP deregulation and
cancer progression [4–6].
This paper will mainly focus on the biological functions
of TCTP and malignant transformation induced by TCTP.
Furthermore, the clinical implications of TCTP in human
cancers will also be discussed.
2. Featuresof TCTP mRNA and Protein
2.1. TCTP mRNA. The human TPT1 gene coding for
TCTP spanning about 4.2kb, consists of six exons and
ﬁve introns [7]. Two alternative polyadenylation signals
at 3 UTR generated two mRNA transcripts that diﬀer in
the length of 3 UTR. In all mammalian tissues tested,
both types of mRNAs are expressed at diﬀerent ratios,
and the shorter transcript is usually expressed more abun-
dantly [2]. Sequence analyses of TCTP transcripts indi-
cated that the 5 UTR is CG-rich with a high degree
of secondary structure. TCTP mRNA has a 5  terminal
oligopyrimidine tract (5 TOP), which is a signature of
translationally controlled mRNAs [8]. Although AU-rich2 Biochemistry Research International
regions and AUUA elements have been identiﬁed at the
3 UTR, they do not match classical mRNA instability
elements [1].
2.2. TCTP Protein. As revealed by sequence alignment of
TCTP in more than 30 diﬀerent species, TCTP is highly
conserved over a long-term evolution. A cluster of invari-
a n tr e s i d u e sw e r el o c a t e do no n es i d eo ft h eβ-stranded
“core” domain that is important for molecular interactions
[1]. Thaw et al. found that the “core” domain displays
signiﬁcant similarity to that of the Mss4/Dss4 protein
family upon analyzing the solution structure of TCTP from
Schizosaccharomyces pombe [1, 9]. TCTP is also a novel small
molecular weight (23kDa) heat shock protein that protects
cells from thermal shock by functioning as a molecular
chaperone [10].
2.3. Transcriptional and Translational Regulation. Previous
reports demonstratedthatexpression ofTCTPis regulatedat
the level of the transcription as well as the translation [2, 11].
TCTP is translationally regulated: abundant TCTP mRNA
was found as untranslated mRNP particles [11], an increase
in TCTP synthesis under the treatment of transcription
inhibitor,actinomycinD[12],a5 -TOPofTCTPmRNAand
its extended secondary structure [8].
Comparing the promoter region of TCTP in human,
mouse,rat,rabbit,anddogpredictedthetranscriptionfactor
bindingsitesofTCTP.Notsurprisingly,thepromoterregions
of TCTP are also highly conserved among these species.
Andree et al. further demonstrated that the transcription of
TCTP is controlled by cAMP signaling via phosphorylation-
dependent activation of CRE/CREB interaction [7]. In our
previousstudy, weutilized chromatinimmunoprecipitation-
based (ChIP-based) cloning strategy to identify genes poten-
tially regulated by CHD1L (chromodomain helicase/ATPase
DNA binding protein 1-like gene) [13]. From this strategy,
we isolated 35 CHD1L-binidng loci and characterized a
speciﬁc CHD1L-binding motif (C/A-C-A/T-T-T-T). Two
CHD1L-binding motifs have been identiﬁed at −748bp and
−851bpinthe5 -ﬂankingregionofTCTP[13].Importantly,
we have demonstrated that the binding of CHD1L to
the promoter region of TCTP dramatically activates the
transcription of TCTP.
3.Biological Functions
3.1. Growth and Development. A knockout mouse approach
had been used to investigate the role of TCTP in devel-
opment. As demonstrated by Chen et al., heterozygous
mice (TCTP+/−) were viable, fertile, and morphologically
similar to their wild-type littermates, while the homozygous
(TCTP−/−) were embryonic lethal. Moreover, TCTP−/−
embryo at embryonic stage day 5.5 (E5.5) suﬀered from
reduced cell numbers and increased apoptosis and subse-
quentlydiedaroundE9.5–10.5[14].ThissuggeststhatTCTP
is essential for normal development. The human TCTP
(hTCTP) protein sequence is 50% identical with Drosophila
TCTP (dTCTP) [15]. They also indicated that silencing of
dTCTP by RNA interference resulted in the reduced cell size,
cell number, and organ size. Also, as Rheb is an important
regulator in TSC-mTOR pathway, TCTP might function as
a growth-regulating protein by the stimulation of GDP/GTP
exchangeofhumanRheb(hRheb)viabindingtohRheb[15].
On the contrary, Rehmann et al. argues that TCTP does
not act as a guanine nucleotide exchange factor (GEF) of
Rheb [16]. Therefore, additional experiments are essential
to further substantiate the role of TCTP in cell growth
regulation through the TSC-mTOR pathway.
3.2. Regulation of Cell Cycle and Apoptosis. Gachet et al.
demonstrated that TCTP interacts with microtubules during
G1, S, G2, and early M phase of the cell cycle [17]. During
mitosis, it binds to the mitotic spindle and detaches from
thespindleduringthemetaphase-anaphasetransition.When
TCTP is overexpressed in bovine mammary epithelial cells,
rearrangement of microtubule and growth inhibition can
be observed [17]. Two-hybrid screening methods identiﬁed
TCTP as a substrate of polo-like kinase (Plk), which is
involved in the formation and function of bipolar spindles
and Plk phosphorylates TCTP on two serine residues [18].
Abolishing Plk phosphorylation on TCTP-induced mitotic
defects and high incidences of apoptosis, indicating that
phosphorylation of TCTP on two serine residues by Plk plays
an important role in cell mitosis [18].
3.3. Regulation of Self-Renewal and Pluripotency. Home-
odomain transcription factors Oct4 and Nanog have been
i d e n t i ﬁ e da sm a s t e rr e g u l a t o r so fs t e mc e l ls e l f - r e n e w a la n d
pluripotency [19]. Oct4 appears to regulate cell fates in a
quantitative fashion and maintain a critical concentration to
sustain embryonic stem (ES) cell self-renewal [20]. Proteins
associated with the regulatory region of the mouse oct4
gene can be isolated and identiﬁed by mass spectrometry
[21]. Using this strategy, TCTP was found to bind to the
promoter region of oct4. Although tpt1 transcript depletion
can inactivate the transcription of both oct4 and nanog,
TCTP binds only to the oct4 promoter as determined by
ChIP analysis in mouse ES cells [21]. It has also been
suggested that TCTP could regulate oct4 by directly binding
toitsproximalpromoter.However,TCTPmightalsoregulate
nanog indirectly or binds to its distal promoter. These data
suggest that TCTP is a potential regulator of self-renewal and
pluripotency.
4. Malignant Transformation by
TCTP duringCancer Progression
Althoughtherearemanydistinct typesofhumancancers,six
essential alterations to normal cells are believed to deﬁne the
progression of most human malignancies: they are evasion
of apoptosis, sustained angiogenesis, accelerated cell cycle
progression, tissue invasion and metastasis, self-suﬃciency
in growth signals, and insensitivity to antigrowth signals.Biochemistry Research International 3
Therefore, the information described below provides us with
some insights into the oncogenic role of TCTP.
4.1. Diﬀerential Expression of TCTP in Cancer. Independent
studies indicated that TCTP is preferentially expressed in
cancer. In human colon cancer, the level of TCTP mRNA was
detected in three human colon carcinoma cell lines (SNU-
C2A, SNU-C4, and SNU-C5). The expression levels were
not equal among these cell lines. SNU-C5 with the highest
expression grew at the fastest rate; however, SNU-C2A with
the lowest expression grew at the slowest rate [4]. Higher
expression level of TCTP was also observed in prostate
cancer specimens compared to normal prostate tissues [5].
In hepatocellular carcinoma (HCC), the expression level of
TCTP was detected in a retrospective cohort of 118 HCC
patients. As a result, TCTP was found to be signiﬁcantly
upregulated in tumor tissues when compared to their adja-
cent noncancerous tissues. Overexpression of TCTP (deﬁned
as 2 fold increase) was detected in 40.7% of HCC specimens
[6].
4.2. Antiapoptosis. Overexpression of TCTP was detected in
many types of tumors and its downregulation decreases the
viability of those cells [3]. These suggest that TCTP is a
p r o s u r v i v a lf a c t o ri nn o r m a la n dc a n c e rc e l l s .
Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic
protein identiﬁed as an early gene induced during diﬀerenti-
ation of ML-1 myeloid leukemia cells. It is a member of Bcl-2
familythatplaysapivotalroleinanimaldevelopment.Zhang
et al. found that TCTP interacts with Mcl-1, but not any
other Bcl-2 family member. Further, the depletion of Mcl-1
rapidlydestabilizedTCTPinanosteosarcomacelllineU2OS,
supporting the conclusion that Mcl-1 serves as a chaperone
of TCTP, binding and stabilizing TCTP in vivo [22]. On the
contrary, Liu et al. suggest that TCTP may also serve as a
molecular chaperone and cofactor of Mcl-1, in which the
association between TCTP and Mcl-1 is essential for both to
function [23].
It has been reported that TCTP interacts with Bcl-
xL, an antiapoptotic protein that maintains the integrity
of the mitochondrial membrane [24]. They found that
the N-terminal region of TCTP is responsible for its
interaction with the Bcl-xL BH3 domain, which is critical
for eliciting antiapoptotic properties. They also proposed
that TCTP might inhibit T-cell apoptosis by preventing the
phosphorylation/inactivation of Bcl-xL. More recently, the
crystal structure of TCTP provides new insights into its
antiapoptotic activity. The H2-H3 helices of TCTP share
a structural similarity to the H5-H6 helices of Bax [25].
Mutation of residues (E109 and K102) close to the turn
between the two helices H2 and H3 of TCTP reduces the
antiapoptotic eﬀect of TCTP on Bax-induced apoptosis,
indicating that H2-H3 helices of TCTP play an important
role in the inhibition of apoptosis. Despite the lack of
evidence to support the binding between TCTP and Bax
[22, 23, 25], Susini et al. suggested that the anchorage of
TCTP into the mitochondrial membrane could inhibit the
dimerization of Bax and subsequent Bax-induced apoptosis.
4.3. Mitotic Defects and Chromosome Missegregation. In
mitosis, APC is activated by binding to Cdc20, and this is
dependent on high Cdk1 activity [26]. Subsequently, the
active APC recognizes securin and cyclin B, thereby provok-
ing their degradation. Degradation of cyclin B inactivates
Cdk1, which subsequently permits mitotic exit [27]. The
microtubule binding activity and Plk phosphorylation sites
indicate that TCTP is an important gene in the regulation
of mitotic progression [17, 18]. As reported in our previous
study, the role of TCTP in cell cycle progression has been
fully investigated by overexpressing TCTP in HCC cell lines.
As a result, TCTP has no obvious eﬀect on G1/S transition;
however, when cells were released after synchronization at
the prometaphase, an accelerated mitotic exit was observed
in TCTP-overexpressing cells [6]. Mechanistic study demon-
strated that TCTP promoted the ubiquitin-proteasome
degradation of Cdc25C during mitotic progression, which
caused the failure in the dephosphorylation of Cdk1-Tyr15
and decreased Cdk1 activity. As a consequence, the sudden
drop of Cdk1 activity in mitosis induced a faster mitotic exit
andchromosomemissegregation,whichledtochromosomal
instability (Figure 1). We did not observe any obvious diﬀer-
ence in cyclin B1 expression level between control and TCTP
overexpressing cells, suggesting that the TCTP-mediated
faster mitotic exit might not be related to APC-mediated
degradation of cyclin B1. Xenograft experiments further
supported our notion that the overexpression of TCTP could
induce mitotic defects and chromosome missegregation [6].
4.4. Migration and Metastasis. Metastasis is the ﬁnal step
in solid tumor progression and is the most common cause
of death in cancer patients [28]. Metastasis is a multistep
process, all of which must be successfully completed before
giving rise to a metastatic tumor. It has been reported that
TCTP is preferentially expressed in colon cancer cell lines
(LoVo, SW620) with highly metastatic potentials. Depletion
of TCTP by shncRNA-TCTP in LoVo cells signiﬁcantly
reduced the number of the hepatic surface metastases in
nude mice [29]. Recently, our group has studied the motile
and invasive capabilities of TCTP in vitro and in vivo.A sa
result,thenumberofinvadedcellswassigniﬁcantlyincreased
in TCTP-overexpressing cells. An experimental metastasis
assay was used to examine the metastatic nodules formed
in the livers of SCID mice after inoculation with TCTP-
overexpressing cells. Cells were injected through the tail-vein
of SCID mice, metastatic nodules were counted at 8 weeks
after injection. The number of metastatic nodules on the
surface of the liver was signiﬁcantly higher in mice injected
with TCTP-transfected cells.
5. ClinicalImplication of TCTP in
Human Cancers
Overexpression of TCTP was found in diﬀerent types of
cancers, including colon cancer [4], prostate cancer [5],
and liver cancer [6]. In our previous study, overexpression
of TCPT was detected in 40.7% (48 of 118) of HCC
cases. Clinically, overexpression of TCTP was signiﬁcantly4 Biochemistry Research International
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Figure 1: Mechanistic diagram showing the eﬀect of abnormal regulation of TCTP/Cdc25C/Cdk1 pathway in HCC development. (Upper
panel) Under the normal mitotic progression, Cdc25C activates Cdk1 by the dephosphorylation of Thr14 and Tyr15 in Cdk1. The level of
active Cdk1 is a key factor for maintaining the mitotic state and functions as a key switch for cell division. (Lower panel) During the HCC
development, TCTP is overexpressed in over 40% of HCC cases. Overexpression of TCTP promotes the ubiquitin-proteasome degradation
of Cdc25C, which leads to the failure in the dephosphorylation of Cdk1 on Tyr15 and decreases Cdk1 activity. As a consequence, the sudden
drop of Cdk1 activity in mitosis induces a faster mitosis exit and chromosome missegregation, which leads to aneuploidy and CIN, ﬁnally
causing cancer development.
associated with the advanced tumor stage and overall
survival time of HCC patients. TCTP was also determined
as an independent marker associated with poor prognostic
outcomes [6]. Moreover, our recent study also indicated
that the overexpression of TCTP was signiﬁcantly associated
withextrahepatic metastases (e.g., bone, lymph node, and
kidney) among HCC patients.
By comparing the proteome of a melanoma cell line
(MeWo) and their chemoresistant counterpart, TCTP was
also found to be one of the proteins preferentially expressed
in chemoresistant melanoma cell lines [30].
6. Conclusions andFutureDirections
Due to the ubiquitous expression and high-degree conser-
vation, TCTP protein underlines its important functions in
the cell. An increasing number of research investigations
are being conducted in this area, particularly into the eﬀect
of TCTP during cancer progression. It is implicated in cell
growth, cell cycle progression, apoptosis, and regulation
in pluripotency. Although TCTP is not tumor-speciﬁc,
preferential expression of TCTP in diﬀerent types of cancer
underlines the importance of TCTP in cancer progression.
As summarized in this paper, TCTP mainly exerts its
tumorigenic function via inhibiting apoptosis, accelerating
mitotic exit, inducing invasion and metastasis, and so on.
By using molecular biological techniques, we demonstrated
a molecular pathway, TCTP/Cdc25c/Cdk1, which plays
an important role in hepatocarcinogenesis by accelerating
mitotic progression and inducing CIN (Figure 1). CIN is a
hallmarkofmanytypesofhumancancersandissigniﬁcantly
associated with poor prognosis. Thus, characterization of
this novel pathway will greatly facilitate our insights into
the link between aneuploidy cancer development. To better
understand the oncogenic mechanism of TCTP, our current
work is focusing on the DNA-binding activity of TCTP and
identifying its speciﬁc binding motifs. Future research on the
regulatory network of TCTP will improve our understanding
of this oncogene and may ultimately contribute to the
development of more accurate treatment modalities.
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